Nonalcoholic Steatohepatitis: A Review
- PMID: 32207804
- DOI: 10.1001/jama.2020.2298
Nonalcoholic Steatohepatitis: A Review
Erratum in
-
Typographical Error.JAMA. 2020 Apr 28;323(16):1619. doi: 10.1001/jama.2020.5249. JAMA. 2020. PMID: 32343314 No abstract available.
Abstract
Importance: Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant. Despite its importance, NASH is underrecognized in clinical practice.
Observations: NASH affects an estimated 3% to 6% of the US population and the prevalence is increasing. NASH is strongly associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome. Although a number of noninvasive tests and scoring systems exist to characterize NAFLD and NASH, liver biopsy is the only accepted method for diagnosis of NASH. Currently, no NASH-specific therapies are approved by the US Food and Drug Administration. Lifestyle modification is the mainstay of treatment, including dietary changes and exercise, with the primary goal being weight loss. Substantial improvement in histologic outcomes, including fibrosis, is directly correlated with increasing weight loss. In some cases, bariatric surgery may be indicated to achieve and maintain the necessary degree of weight loss required for therapeutic effect. An estimated 20% of patients with NASH will develop cirrhosis, and NASH is predicted to become the leading indication for liver transplants in the US. The mortality rate among patients with NASH is substantially higher than the general population or patients without this inflammatory subtype of NAFLD, with annual all-cause mortality rate of 25.56 per 1000 person-years and a liver-specific mortality rate of 11.77 per 1000 person-years.
Conclusions and relevance: Nonalcoholic steatohepatitis affects 3% to 6% of the US population, is more prevalent in patients with metabolic disease and obesity, progresses to cirrhosis in approximately 20% of cases, and is associated with increased rates of liver-specific and overall mortality. Early identification and targeted treatment of patients with nonalcoholic steatohepatitis are needed to improve patient outcomes, including directing patients toward intensive lifestyle modification to promote weight loss and referral for bariatric surgery as indicated for management of obesity and metabolic disease.
Comment in
-
Nonalcoholic Steatohepatitis.JAMA. 2020 Sep 1;324(9):899. doi: 10.1001/jama.2020.10434. JAMA. 2020. PMID: 32870291 No abstract available.
Similar articles
-
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9. Z Gastroenterol. 2019. PMID: 30965381 Review. English.
-
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14. Am J Gastroenterol. 2017. PMID: 28195177
-
Nonalcoholic fatty liver disease: a systematic review.JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. JAMA. 2015. PMID: 26057287 Review.
-
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1. Yakugaku Zasshi. 2019. PMID: 31474630 Review. Japanese.
-
The role of bariatric surgery in the management of nonalcoholic steatohepatitis.Curr Opin Gastroenterol. 2021 May 1;37(3):208-215. doi: 10.1097/MOG.0000000000000721. Curr Opin Gastroenterol. 2021. PMID: 33769376 Review.
Cited by
-
Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis.Front Endocrinol (Lausanne). 2024 Oct 15;15:1457589. doi: 10.3389/fendo.2024.1457589. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39473504 Free PMC article.
-
Correlative Quantitative Raman Chemical Imaging and MCR-ALS in Mouse NASH Model Reveals Direct Relationships between Diet and Resultant Liver Pathology.Chem Biomed Imaging. 2024 Jun 18;2(8):577-583. doi: 10.1021/cbmi.4c00027. eCollection 2024 Aug 26. Chem Biomed Imaging. 2024. PMID: 39473991 Free PMC article.
-
Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach.Eur Cardiol. 2024 Jun 19;19:e06. doi: 10.15420/ecr.2023.34. eCollection 2024. Eur Cardiol. 2024. PMID: 38983581 Free PMC article. Review.
-
Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis.Biomark Res. 2024 Jan 9;12(1):6. doi: 10.1186/s40364-023-00555-9. Biomark Res. 2024. PMID: 38195587 Free PMC article.
-
Update on genetics and epigenetics in metabolic associated fatty liver disease.Ther Adv Endocrinol Metab. 2022 Oct 28;13:20420188221132138. doi: 10.1177/20420188221132138. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 36325500 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical